David Avigan, M.D.
Dr. Avigan is Assistant Professor of Medicine, Harvard Medical School, aand Director of Hematological Malignancies and Bone Marrow Transplantation, Beth Israel Deaconess Medical Center and Dana Farber Harvard Cancer Center, Boston, MA.
Within the last 12 months Dr. Avigan reports research support from Genzyme and Berlex.
This activity is made possible by an unrestricted educational grant from 
.
Estimated course time: 1 hour(s).
Albert Einstein College of Medicine – Montefiore Medical Center designates this enduring material activity for a maximum of 0.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
In support of improving patient care, this activity has been planned and implemented by Albert Einstein College of Medicine-Montefiore Medical Center and InterMDnet. Albert Einstein College of Medicine – Montefiore Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Upon completion of this Cyberounds®, you should be able to:
Identify the unique biological characteristics of AML in the elderly and their impact on response to therapy
Discuss therapeutic trials in elderly patients with AML which examine the role of aggressive and low intensity chemotherapy
Define the role of autologous and allogeneic hematopoietic transplantation in elderly patients with AML
Discuss the role of novel agents as therapy for elderly patients with AML.
